ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 36.17 percent. This is a 33.33 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $38.285 million which beat the analyst consensus estimate of $37.020 million by 3.42 percent. This is a 406.95 percent increase over sales of $7.552 million the same period last year.